




RealRate

PHARMACEUTICAL 2013

American BIO Medica CORP
Rank 134 of 218



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of American BIO Medica CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of American BIO Medica CORP compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 55% points. The greatest weakness of American BIO Medica CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 146% points.

The company's Economic Capital Ratio, given in the ranking table, is 184%, being 36% points below the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	3,520
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,146
Liabilities, Non-Current	145
Other Assets	67
Other Compr. Net Income	0
Other Expenses	8,020
Other Liabilities	124
Other Net Income	10
Other Revenues	9,343
Property and Equipment	1,192
Research and Development	207
Selling, General and Administrative Expense	2,237

Output Variable	Value in 1000 USD
Assets	4,779
Liabilities	3,415
Expenses	10,464
Revenues	9,343
Stockholders Equity	1,364
Net Income	-1,111
Comprehensive Net Income	-1,111
BaseVar	14,006
ECR before LimitedLiability	45%
Economic Capital Ratio	184%